Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HMGCR | P04035 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 3/20 | 0.32 |
| ▸ | TLR4 | O00206 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26358020 | 0.86 | ALDH1A1 (0.38) | CYP2C9ALDH1A1MAPTLMNAKMT2A | |
| SCHEMBL24326028 | 0.84 | SLC1A3 (0.32) | LMNASLC1A3SLC1A2SLC1A1 | |
| Hydrochloric Acid SCHEMBL29006945 | 0.82 | LMNA (0.40) | LMNACNR2SLC1A3SLC1A2SLC1A1 | |
| Hydrochloric Acid SCHEMBL29006999 | 0.82 | LMNA (0.43) | LMNAKMT2AMEN1SLC1A3SLC1A2 | |
| SCHEMBL24326601 | 0.80 | ALDH1A1 (0.38) | CYP2C9ALDH1A1MAPTLMNAKMT2A | |
| Hydrochloric Acid SCHEMBL29006970 | 0.78 | CYP2C9 (0.38) | CYP2C9ALDH1A1MAPTLMNAKMT2A | |
| Hydrochloric Acid SCHEMBL29006968 | 0.78 | CYP2C9 (0.38) | CYP2C9ALDH1A1MAPTLMNAKMT2A | |
| SCHEMBL6750673 | 0.77 | TLR4 (0.38) | CYP2C9ALDH1A1MAPTLMNAKMT2A | |
| SCHEMBL14144838 | 0.75 | PRKCA (0.38) | LMNACNR2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL30457829 | 0.75 | MAPT (0.38) | CYP2C9ALDH1A1MAPTLMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119426-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119426-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | PNP, TYMP, NME2 | CYP2C9 901/4885ALDH1A1 3872/4885MAPT 3579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.